Red Clover Isoflavones, Hormones and Safety

Table of Contents

1. The Four Isoflavones
2. What the Body Does With Them
3. Equol and the Producer Divide
4. What "Phytoestrogen" Means at the Receptor
5. Clover Disease: the Sheep That Started It
6. Hormone-Sensitive Conditions
7. Tamoxifen and Aromatase Inhibitors
8. Anticoagulants, Antiplatelets and Surgery
9. Pregnancy, Breastfeeding and Children
10. Other Interactions, Liver and Drug Metabolism
11. Side Effects Reported in Trials
12. Product Variability and Standardization
13. Who the Research Raises Concerns For
14. Key Research Papers
15. Safety and Disclaimer
16. Connections
17. Featured Videos

The Four Isoflavones

Red clover (Trifolium pratense) is one of the richest plant sources of isoflavones, a class of polyphenol found chiefly in the legume family. Four matter:

• Biochanin A — abundant in the dried flowering tops. A methylated compound, relatively weak at the estrogen receptor in its own right.
• Formononetin — the other abundant one, also methylated and weak as it stands.
• Genistein — present in smaller amounts in the plant but one of the two most receptor-active isoflavones known.
• Daidzein — likewise present in smaller amounts, and the precursor of the more potent metabolite equol.

This composition is red clover's signature. Other isoflavone sources have different ratios, and the heavy load of biochanin A and formononetin is what distinguishes clover chemically. The compounds and their receptor behaviour are reviewed in Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? (The Journal of Steroid Biochemistry and Molecular Biology, 2005) — find it on PubMed. What a clinical-grade extract actually contains was characterized in The chemical and biologic profile of a red clover (Trifolium pratense L.) phase II clinical extract (The Journal of Alternative and Complementary Medicine, 2006) — find it on PubMed. Evidence tier: analytical chemistry.

The plant also contains coumarin-type compounds, which matter for the bleeding caution below, along with the usual mix of flavonoids and other plant constituents that are unlikely to be pharmacologically important at supplement doses.

What the Body Does With Them

The two abundant clover isoflavones are, in effect, precursors. During digestion and first-pass metabolism, a methyl group is removed from each:

1. Biochanin A is demethylated to genistein.
2. Formononetin is demethylated to daidzein.

So swallowing red clover largely means delivering genistein and daidzein to the bloodstream by a slightly indirect route. Both then undergo extensive conjugation in the intestine and liver — attachment of glucuronide and sulfate groups — and circulate predominantly in these conjugated forms, which are far less active at the receptor than the free compound. Only a small fraction circulates unconjugated and available to bind.

This is one reason the herb's clinical effects are modest even though its compounds look impressive in a test tube. Laboratory studies often expose cells to free isoflavone at concentrations well above the free fraction achievable in human plasma from a capsule. Evidence tier: human pharmacokinetics. A broader view of the metabolic route is available via a PubMed topic search on isoflavone demethylation and metabolism.

Equol and the Producer Divide

Daidzein has one further possible fate. Certain intestinal bacteria convert it into equol, a metabolite with notably greater estrogen-receptor activity and a longer half-life than daidzein itself. Whether this happens depends on which bacteria a person carries, and roughly a quarter to a half of Western adults are equol producers, with higher proportions reported in some East Asian populations. The chemistry and its discovery are covered in Equol: history, chemistry, and formation (The Journal of Nutrition, 2010) — find it on PubMed. Evidence tier: human metabolism research.

The clinical implication cuts both ways, which is why it appears on this safety page and not only on the benefits pages. If equol producers get a stronger estrogenic signal from the same capsule, they are also the people for whom estrogen-related cautions would apply most forcefully. And since nobody knows their own status without a specialist test that is not part of routine care, an individual buying red clover cannot know which group they are in.

The wider clinical importance of this metabolite was argued in The clinical importance of the metabolite equol — a clue to the effectiveness of soy and its isoflavones (The Journal of Nutrition, 2002) — find it on PubMed. It is cited here as scientific context for how isoflavones behave in the human gut, not as a recommendation about any particular food.

What "Phytoestrogen" Means at the Receptor

A phytoestrogen is a plant compound whose shape lets it occupy an estrogen receptor. Three properties determine what that actually does.

Potency. Isoflavones are weak — commonly described as orders of magnitude less potent than estradiol at the receptor. Red clover is not hormone therapy in a capsule, and anyone hoping it will substitute for one will be disappointed.

Receptor preference. Isoflavones bind preferentially to estrogen receptor beta over estrogen receptor alpha. The two receptors have different tissue distributions and, in some tissues, opposing effects on cell growth. This preference is the basis of the hope that isoflavones behave like a natural selective estrogen receptor modulator — estrogen-like in some tissues, neutral or mildly blocking in others. It is a reasonable model. It is not a guarantee of tissue selectivity in any given person.

Context dependence. A weak receptor agonist behaves differently depending on how much of the body's own estrogen is present. When estrogen is low — after menopause — a weak agonist adds a small signal. When estrogen is high, the same compound occupying the receptor may partially block the stronger natural hormone. This is why the effect of the same supplement can differ between a premenopausal and a postmenopausal woman, and it is why "it is only a weak estrogen" is not by itself a safety argument.

Clover Disease: the Sheep That Started It

The entire phytoestrogen field began with a farming disaster. In Western Australia in the 1940s, ewes grazing clover-rich pasture developed widespread infertility, along with reproductive-tract abnormalities. The condition became known as clover disease, and investigation traced it to isoflavones — formononetin prominent among them — acting as estrogens in the animals' bodies.

The species most implicated was subterranean clover, a close relative rather than red clover itself, but the isoflavone chemistry is shared. This episode is the first hard demonstration that plant compounds could produce substantial estrogenic effects in a mammal, and it is the historical foundation of everything on this page. It is described in the 2005 review cited above.

It also supplies a useful sense of scale, in both directions. Grazing sheep consumed enormous quantities of fresh clover relative to body weight — far more isoflavone than any human supplement delivers, which is genuinely reassuring. But the episode establishes that these compounds are not inert decorations. At sufficient exposure they do real reproductive things, and that is why "it is just a plant" is not a safety argument either. Evidence tier: veterinary observation and investigation.

Hormone-Sensitive Conditions

This is the most important section on the page.

Several conditions are driven or worsened by estrogen: breast cancer, uterine (endometrial) cancer, ovarian cancer, endometriosis and uterine fibroids. Since red clover's isoflavones exert estrogenic activity, the research raises a concern for all of these.

The reassuring evidence. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial (Breast Cancer Research, 2004) gave 205 women aged 49–65 a red clover tablet (26 mg biochanin A, 16 mg formononetin, 1 mg genistein and 0.5 mg daidzein) or placebo every day for one year; 177 finished. Mammographic breast density — a marker watched as a possible sign of estrogenic breast stimulation — fell in both groups, with no significant difference between them, and there were no significant effects on oestradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH) or hot flushes over one year — find it on PubMed. And Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer (Menopause International, 2008) gave 40 mg of red clover isoflavones a day or placebo for three years to 401 healthy women aged 35–70 who had at least one close (first-degree) relative with breast cancer. Breast density, endometrial thickness (the womb lining), cholesterol, follicle-stimulating hormone and bone density did not differ between the groups, and side effects were similar — find it on PubMed. Evidence tier: randomized clinical trials of one and three years, safety endpoints.

The concerning evidence. Laboratory work points the other way. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo (Cancer Research, 1998) showed that genistein — the product of red clover's biochanin A — can stimulate the growth of hormone-sensitive breast cancer cells — find it on PubMed. Evidence tier: preliminary, cell culture and animal.

How to hold both. These findings are not actually contradictory. Cell and animal studies use conditions and concentrations that a supplement may never produce in a person. The human trials cited here ran for one year and, at the longest, three years; they measure markers such as breast density and cannot see what a decade of daily plant estrogen does to hormone-sensitive tissue — no trial has run long enough or been large enough to answer that. In short: the human safety data up to three years are reassuring, the long-term data do not exist, and the laboratory work provides a real mechanistic reason for concern.

For anyone with a personal history of breast cancer, endometrial cancer or ovarian cancer, the concern rests on red clover’s estrogen-like activity described above and on the mouse finding with tamoxifen described below. The same concern applies to active endometriosis and symptomatic uterine fibroids, both estrogen-driven conditions in which any added estrogenic signal adds to what drives the disease.

Tamoxifen and Aromatase Inhibitors

Two classes of drug used in hormone-receptor-positive breast cancer deserve specific attention, because red clover interacts with the logic of both.

Tamoxifen works by blocking estrogen receptors in breast tissue. Introducing a compound that occupies the same receptors raises an obvious question. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice (Cancer Research, 2002) found in an animal model that dietary genistein could counteract tamoxifen's tumour-suppressing effect — find it on PubMed. Evidence tier: preliminary, animal. This has not been demonstrated in humans, and the human observational literature on isoflavone intake during breast cancer treatment is not uniformly alarming. Because tamoxifen is prescribed to prevent the cancer returning, the possible harm this mouse study points to is recurrence; its authors concluded that caution is warranted for postmenopausal women consuming dietary genistein while on tamoxifen therapy.

Soy foods are a different exposure. For isoflavones eaten in food rather than taken as capsules, the After Breast Cancer Pooling Project combined 9,514 women in the United States and China who had been diagnosed with invasive breast cancer and followed them for an average of 7.4 years. Women whose soy foods supplied 10 mg or more of isoflavones a day after diagnosis had a lower risk of the cancer coming back (hazard ratio 0.75), and a lower risk of death that was not statistically significant — Soy food intake after diagnosis of breast cancer and survival (The American Journal of Clinical Nutrition, 2012) — find it on PubMed. These were soy foods, a group that includes fermented foods such as miso, natto and tempeh, not red clover extracts, and the study was observational, so it shows an association rather than proof of cause. Evidence tier: observational cohort study.

Aromatase inhibitors work by suppressing the enzyme that produces estrogen from androgen precursors, driving estrogen levels very low. Some flavonoids and isoflavones inhibit aromatase in laboratory systems — see, for example, Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes (The Journal of Steroid Biochemistry and Molecular Biology, 1994) — find it on PubMed. That might sound complementary, but the more relevant concern runs the other way: in a body where an aromatase inhibitor has driven estrogen almost to zero, an exogenous weak estrogen has an unusually clear field at the receptor, with no competition from the body's own hormone. Evidence tier: preliminary, in vitro; the clinical interaction is theoretical.

What the evidence says for both drugs: an interaction with red clover has not been demonstrated in humans. The evidence is the mouse study above, in which dietary genistein cancelled tamoxifen’s tumour-suppressing effect, and laboratory work on aromatase. The possible harm the research points to is the cancer coming back, which is why this concern is the most serious one on the page.

Anticoagulants, Antiplatelets and Surgery

Red clover contains coumarin-type compounds. Coumarin itself is not an anticoagulant — the drug warfarin is a synthetic derivative, and spoiled sweet clover hay famously caused fatal bleeding in cattle because fungal action converted its coumarin into dicoumarol. Red clover as sold is not spoiled hay, and the direct anticoagulant content of a normal preparation is low.

Potential interactions between alternative therapies and warfarin (The American Journal of Health-System Pharmacy, 2000) lists red clover — together with clove, garlic, ginger, sweet clover and others — among herbal products that “may potentially increase the risk of bleeding or potentiate the effects of warfarin therapy”, and notes that nearly all such information comes from laboratory data, animal studies or individual case reports — find it on PubMed. Evidence tier: theoretical and mechanistic; documented human case reports specific to red clover are sparse. That last point is stated deliberately: this caution rests on chemistry and prudence rather than on a body of confirmed clinical incidents.

What this means in practice:

• With warfarin, an added bleeding effect would show up as a rise in the international normalized ratio (INR), the blood test used to set the warfarin dose.
• The review covers warfarin. For a direct oral anticoagulant or an antiplatelet such as aspirin or clopidogrel, the concern is the same theoretical additive bleeding effect, without specific data.
• Surgery: the conventional practice for herbs with any theoretical bleeding risk is to stop them roughly two weeks before scheduled surgery, including dental surgery.
• Unusual bruising, nosebleeds or bleeding gums in someone taking red clover with one of these medicines can be signs of an added bleeding effect.

Pregnancy, Breastfeeding and Children

Pregnancy: there is no safety data, and the concern is serious. A compound with demonstrated estrogenic activity would act on a pregnancy whose hormonal environment is finely regulated and where the developing fetus is sensitive to endocrine signals. There is no adequate human safety data, and the clover disease episode establishes that isoflavones can affect mammalian reproductive function. Evidence tier: no human safety data; caution based on mechanism and traditional practice.

Breastfeeding: the same concern applies. Isoflavones can pass into breast milk, and there is no safety data on infant exposure through supplementation.

Children and adolescents: red clover has not been studied in this group. Adding a phytoestrogen during the years of pubertal hormonal development is an experiment nobody has run.

For people trying to conceive, the research raises the same concern, both because of the pregnancy concern and because the reproductive effects of sustained phytoestrogen intake on fertility have not been adequately studied in humans.

Other Interactions, Liver and Drug Metabolism

Hormonal medication. Hormone therapy, combined oral contraceptives and other estrogen-containing or estrogen-modifying drugs may interact with red clover, though the direction and magnitude are unclear — an added weak agonist could in principle either supplement or partially compete with a stronger one. See Menopause & hormone replacement therapy (HRT).

Liver enzymes. Isoflavones including biochanin A have shown inhibitory activity against certain cytochrome P450 enzymes in laboratory systems, raising a theoretical possibility of altering the metabolism of other drugs. Whether this occurs at supplement doses in people is not established. The question matters most for medicines with a narrow therapeutic window, where a small change in blood level makes a difference. The relevant literature can be surveyed via a PubMed topic search on isoflavones and cytochrome P450. Evidence tier: preliminary, in vitro.

Liver injury. Red clover is not a commonly implicated cause of drug-induced liver injury, and the U.S. National Institutes of Health's LiverTox entry treats it as a rare concern. As with any supplement, unexplained fatigue, dark urine, pale stools or yellowing of the eyes are signs of liver injury that hospitals treat as urgent.

Thyroid. Isoflavones as a class have been investigated for effects on thyroid peroxidase, mostly in laboratory settings and mostly in the context of iodine deficiency. The clinical significance for people with adequate iodine appears limited; for people taking thyroid hormone, supplement timing can affect the absorption of the thyroid medication. Evidence tier: preliminary, mostly in vitro.

Side Effects Reported in Trials

In randomized trials, red clover's side effect profile has generally been close to placebo, which is the main reason it is described as well tolerated. Reported effects include:

• Headache — among the more frequently mentioned, though often no more common than with placebo.
• Nausea and mild digestive upset.
• Rash — occasional.
• Breast tenderness — less common; it is an estrogen-like effect.
• Vaginal spotting or bleeding — uncommon. Bleeding after menopause is investigated by doctors whatever supplement someone is taking, because the herb may not be its cause.
• Muscle aches — reported occasionally.

Trial safety data have limits worth naming: participants are usually healthy volunteers, most trials run twelve weeks or so (the two safety trials cited on this page ran one year and three years), and rare adverse events are invisible at these sample sizes. Good tolerability over months or a few years in a screened population is not the same as long-term safety in the general public. The accumulated tolerability literature can be reviewed via a PubMed topic search on Trifolium pratense adverse effects.

Product Variability and Standardization

A safety page has to address dose, and red clover's dose is unusually hard to know. Seasonal variation of red clover (Trifolium pratense L., Fabaceae) isoflavones and estrogenic activity (Journal of Agricultural and Food Chemistry, 2006) documented substantial swings in isoflavone content and measured estrogenic activity depending on season and plant material — find it on PubMed. Evidence tier: analytical chemistry.

The consequences are practical:

• A capsule of unstandardized powdered flower has an unknown isoflavone dose. It could be a fraction of the studied dose or a multiple of it.
• A standardized extract stating milligrams of isoflavones is the only form whose dose can be compared to what trials used — typically 40–80 mg per day.
• Tea made from dried blossoms delivers a variable and generally lower dose. Traditional and pleasant; not a way to reproduce a trial.
• Dietary supplements are not required to demonstrate efficacy before sale in most jurisdictions, and manufacturing quality varies. Third-party testing marks are a partial and imperfect reassurance.
• More is not safer. Nothing in the evidence supports exceeding the studied range, and with a phytoestrogen the theoretical risks scale with dose while the benefits, on current evidence, do not.

What the studied doses did. A 2021 meta-analysis of eight randomized trials (ten comparisons) found that women taking red clover had about 1.7 fewer hot flushes a day than women on placebo (95% confidence interval 3.28 to 0.18 fewer). The difference was clearest in postmenopausal women with five or more hot flushes a day, over 12 weeks, at 80 mg or more of isoflavones a day, and with formulas richer in biochanin A; the authors called for further well-designed studies — find it on PubMed. Evidence tier: meta-analysis of randomized trials.

Who the Research Raises Concerns For

Consolidated, for readers who want one list.

No safety data and a serious theoretical concern, or a known allergy:

• Anyone pregnant or breastfeeding.
• Children and adolescents.
• Anyone with a known allergy to red clover or other legumes.

A specific concern raised by the research:

• Anyone with a personal history of breast, uterine (endometrial) or ovarian cancer, past or present.
• Anyone taking tamoxifen, an aromatase inhibitor or other endocrine cancer therapy.
• Anyone with endometriosis or symptomatic uterine fibroids.
• Anyone taking an anticoagulant or antiplatelet medication.
• Anyone taking hormone therapy or hormonal contraception.
• Anyone with liver disease, thyroid disease, or a bleeding disorder.
• Anyone with surgery scheduled — conventional practice is to stop herbs with a bleeding concern about two weeks beforehand.

For prescription medicines, the interactions known so far are the ones on this page: a possible added bleeding effect with warfarin, the mouse finding with tamoxifen, and theoretical effects on hormone medicines and liver enzymes. Pharmacists can check interactions on the spot.

Key Research Papers

1. Beck V, Rohr U, Jungbauer A. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? — The Journal of Steroid Biochemistry and Molecular Biology, 2005;94(5):499-518. PubMed PMID: 15876415
2. Atkinson C, Warren RM, Sala E, et al. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial — Breast Cancer Research, 2004;6(3):R170-9. PubMed PMID: 15084240
3. Powles TJ, Howell A, Evans DG, et al. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer — Menopause International, 2008;14(1):6-12. PubMed PMID: 18380954
4. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo — Cancer Research, 1998;58(17):3833-8. PubMed PMID: 9731492
5. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice — Cancer Research, 2002;62(9):2474-7. PubMed PMID: 11980635
6. Nechuta SJ, Caan BJ, Chen WY, et al. Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women — The American Journal of Clinical Nutrition, 2012;96(1):123-32. PubMed PMID: 22648714
7. Wang C, Mäkelä T, Hase T, Adlercreutz H, Kurzer MS. Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes — The Journal of Steroid Biochemistry and Molecular Biology, 1994;50(3-4):205-12. PubMed PMID: 8049151
8. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin — The American Journal of Health-System Pharmacy, 2000;57(13):1221-7. PubMed PMID: 10902065
9. Setchell KD, Clerici C. Equol: history, chemistry, and formation — The Journal of Nutrition, 2010;140(7):1355S-62S. PubMed PMID: 20519412
10. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol — a clue to the effectiveness of soy and its isoflavones — The Journal of Nutrition, 2002;132(12):3577-84. Cited as metabolic context. PubMed PMID: 12468591
11. Booth NL, Overk CR, Yao P, et al. Seasonal variation of red clover (Trifolium pratense L., Fabaceae) isoflavones and estrogenic activity — Journal of Agricultural and Food Chemistry, 2006;54(4):1277-82. PubMed PMID: 16478248
12. Booth NL, Overk CR, Yao P, et al. The chemical and biologic profile of a red clover (Trifolium pratense L.) phase II clinical extract — The Journal of Alternative and Complementary Medicine, 2006;12(2):133-9. PubMed PMID: 16566672
13. Booth NL, Piersen CE, Banuvar S, et al. Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: a literature review — Menopause, 2006;13(2):251-64. PubMed PMID: 16645539
14. Kanadys W, Barańska A, Błaszczuk A, et al. Evaluation of Clinical Meaningfulness of Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials — Nutrients, 2021;13(4):1258. PubMed PMID: 33920485
15. PubMed topic search: Trifolium pratense adverse effects safety. Run this search
16. PubMed topic search: biochanin A cytochrome P450 inhibition drug interaction. Run this search

Back to Table of Contents

Back to Table of Contents

Safety and Disclaimer

Red clover is a phytoestrogen with modest and contested benefits and a safety record from trials of up to three years that is reassuring but incomplete. There is no safety data in pregnancy, breastfeeding or childhood, and the research raises concerns for anyone with a hormone-sensitive cancer, endometriosis or uterine fibroids, anyone on endocrine cancer therapy, anticoagulant or antiplatelet medication, or hormone therapy, and anyone with surgery scheduled. A supplement does not replace diagnosis or treatment, and new bleeding, a breast change or an unexplained symptom can have causes other than a herb. This page is educational information, not medical advice, and it cannot account for an individual history.

Connections

• All Herbs
• Red Clover (main page)
• Red Clover Benefits Hub
• Red Clover for Menopause and Hot Flashes
• Red Clover and Bone Density
• Red Clover for Cardiovascular and Cholesterol Health
• Breast Cancer
• Endometrial Cancer
• Ovarian Cancer
• Endometriosis
• Uterine Fibroids
• Menopause & Hormone Replacement Therapy
• Hormone Replacement Therapy Risks: Breast Cancer, Clots & Stroke
• PT/INR
• Prothrombin Time
• Black Cohosh
• Licorice
• Dong Quai

Back to Table of Contents

Featured Videos